Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

In a neuronal overexpression screen focused on kinases and phosphatases, one "hit" was the dual specificity tyrosine phosphorylation-regulated kinase (Dyrk4), which increased the number of dendritic branches in hippocampal neurons. Overexpression of various Dyrk family members in primary neurons significantly changed neuronal morphology. Dyrk1A decreased axon growth, Dyrk3 and Dyrk4 increased dendritic branching, and Dyrk2 decreased both axon and dendrite growth and branching. Kinase-deficient mutants revealed that most of these effects depend on kinase activity. Because doublecortin (DCX), a microtubule-binding protein, regulates cytoskeletal dynamics and neuronal morphogenesis, we investigated the possibility that DCX is a target of Dyrks. We found that overexpression of Dyrk2 and Dyrk3, but not Dyrk1A or Dyrk4, can change DCX phosphorylation status. Mutation of a consensus phosphorylation site for Dyrk kinases at Serine 306 (Ser306) in DCX indicated that this is one target site for Dyrk2 and Dyrk3. Overexpression of Dyrk2 restored altered DCX distribution in the growth cones of dendrites and axons, and partially reversed the morphological effects of DCX overexpression; some of these effects were abrogated by mutation of Ser306 to alanine. These studies implicate Dyrks in the regulation of cytoskeletal organization and process outgrowth in neurons, and suggest that DCX is one relevant Dyrk target.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3556588PMC
http://dx.doi.org/10.1002/cm.21021DOI Listing

Publication Analysis

Top Keywords

dyrk kinases
8
cytoskeletal organization
8
neuronal morphology
8
dyrk4 increased
8
decreased axon
8
overexpression dyrk2
8
dyrk2 dyrk3
8
dcx
7
overexpression
5
dyrk
4

Similar Publications

Dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) play crucial roles in regulating cell growth and brain development. Dysregulation of these kinases is linked to disorders like Down syndrome and cancers. The selective inhibition of DYRK1A over other isoforms remains a significant challenge due to their high structural similarity.

View Article and Find Full Text PDF

The dual-specificity tyrosine-phoshorylation-regulated kinase (DYRK) family are multifunctional enzymes crucial for diverse cellular processes, including signaling through the primary cilium. Their dysregulation has been implicated in various cancers and developmental disorders, highlighting the need to define their interactors and cellular functions to inform targeted therapeutics. In this study, we generate the proximity interactome of DYRK3, identifying 178 proteins involved in a range of cellular processes, including primary cilium biogenesis.

View Article and Find Full Text PDF

Discovery of Dietary Plant Flavonols as Novel Potent Inhibitors Targeting DYRK1A Kinase.

Biomolecules

June 2025

Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON KL7 3N6, Canada.

DYRK1A kinase is a critical regulator in cellular signaling pathways and a promising therapeutic target for neurodegenerative diseases, diabetes and cancers. Despite its significance, the development of potent, selective and safe inhibitors remains a significant challenge. Several natural flavonoids have been reported to inhibit DYRK1A by binding in the ATP-binding pocket, exhibiting antidiabetic properties.

View Article and Find Full Text PDF

Alzheimer's disease (AD) is characterized by the accumulation of tau tangles that aggregate into neurofibrillary tangles (NFT). This study aims to assess binding of [I]IPPI, a recently reported imaging probe for pathological, aggregated tau in AD human hippocampus (HP) postmortem brain slices, and measure effects of drugs known to bind to tau, monoamine oxidase A (MAO-A), and dual specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A). Quantitative [I]IPPI binding was compared between AD (n = 29; 13 male and 16 female) and cognitively normal (CN) (n = 32; 16 male and 16 female) subjects.

View Article and Find Full Text PDF

Harmine-mediated Reduction of Bone Cancer Pain in Rats Correlates With Suppressed DYRK1A/NF-κB Signaling Axis.

J Integr Neurosci

June 2025

Department of Anesthesiology and Pain Research Center, Jiaxing University Affiliated Hospital, The First Hospital of Jiaxing, 314001 Jiaxing, Zhejiang, China.

Background: Bone cancer pain (BCP) is a prevalent chronic pain condition and a common clinical symptom in patients with advanced cancer. It significantly affects the mobility and quality of life of patients; however, current treatments offer limited efficacy. Harmine, a beta-carboline alkaloid extracted from , exhibits anti-inflammatory, anxiolytic, analgesic, and neuroprotective properties.

View Article and Find Full Text PDF